Sep 2026· International journal of urology· Vol 33· 1 citation· 82 references
Medicine
TL;DR
A deeper understanding of primary resistance will be essential for the development of mechanism‐based therapeutic strategies and for achieving durable clinical benefit in patients with mRCC.
Abstract
Immune checkpoint inhibitors have become a standard treatment for patients with metastatic renal cell carcinoma (mRCC). The combination of nivolumab and ipilimumab has demonstrated durable responses and survival benefits; however, approximately 20%–25% of patients exhibit primary resistance and derive limited clinical benefit. This review provides a comprehensive overview of current evidence regarding the incidence, clinical predictors, and biological mechanisms of primary resistance to nivolumab plus ipilimumab in mRCC. Key contributing factors include an immunosuppressive tumor microenvironment, metabolic reprogramming, interferon signaling abnormalities, and T‐cell exhaustion. Potential strategies to overcome resistance, such as vascular endothelial growth factor receptor–targeted combinations, biomarker‐driven treatment selection, and novel immune checkpoint targets, are also discussed. A deeper understanding of primary resistance will be essential for the development of mechanism‐based therapeutic strategies and for achieving durable clinical benefit in patients with mRCC.
The treatment landscape for metastatic renal cell carcinoma (mRCC) has changed significantly with the advent of combination therapies based on immune checkpoint inhibitors (ICIs). Currently, nivolumab plus ipilimumab (NIVO+IPI) and ICI plus tyrosine kinase inhibitor (IO–TKI) combination therapies are widely used as fir...
H. Hirata· International journal of uro...· 0 citations
Emerging clinical evidence and mechanistic insights into OV–ICI synergy are synthesized to inform rational trial design, refine combination strategies, and accelerate the development of precision immuno-oncology approaches.
In recent years, immune checkpoint inhibitors (ICIs), such as nivolumab, ipilimumab, pembrolizumab, and atezolizumab have substantially improved the prognosis of patients with advanced renal cell carcinoma. These agents have greatly changed the management of advanced renal cell carcinoma, shifting the treatment paradig...
Li Chen, Jie Cheng, Shi-Long Mao· Frontiers in Oncology· 0 citations
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of several malignancies; however, their efficacy in platinum-resistant ovarian cancer (PROC) remains limited. The immunosuppressive tumor microenvironment (TME) in ovarian cancer constitutes a major barrier to effective antitumor immunity, pro...
E. Giudice, A. Spinazzola, C. Floudas et al.· Cancer Treatment Reviews· 0 citations
Renal cell carcinoma (RCC), particularly its clear-cell subtype (ccRCC), is characterized by metabolic reprogramming and a complex tumor microenvironment that influence responses to immune checkpoint inhibitors (ICIs). Despite clinical advances, therapeutic resistance remains a major hurdle. Here we review the molecula...
M. Milella, Francesco Lasorsa, M. Rutigliano et al.· Cells· 0 citations
Lenvatinib plus pembrolizumab provides significant improvements in PFS and objective response compared with sunitinib, while nivolumab plus ipilimumab demonstrates durable long-term survival benefits.
Zhumagazin Zhanabay Derbesinovich· Oncology, Nuclear Medicine a...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.